The recent performance from Gilead Sciences has analysts and investors concerned about the future. Argus believes that the headwinds are blowing harder than the tailwinds for the company.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Friday morning include Alphabet, Amazon, Dow Chemical, Ford, Gilead, Harley-Davidson and Western Digital.
The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
Overall, the Gilead Sciences report was not good and investors took to dumping the stock. On the other hand, this could provide a buying opportunity since shares are just off of their…
Chris Lange The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Gilead Sciences, Sprint, Starbucks, Southwest Airlines, Texas Instruments, Walt Disney and Nordstrom.
Although Gilead Sciences is one of the world’s leading biotech companies, an earnings beat in its latest report was not enough to satisfy investors.
Chris Lange Gilead Sciences is scheduled to release its second-quarter financial results after the markets close on Monday.
Chris Lange 24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
With many stocks having just hit record highs, investors need at least a bit of an explanation here. One thing likely contributing to the gains is the endless effort in share buybacks…
The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if RBC…
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a…
Standard & Poor's has now shown that the first quarter of 2016 saw a 12% rise in buyback spending to a whopping $161.4 billion.
Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped about 17.5%…
Chris Lange 
